PLX · Protalix BioTherapeutics Inc
United States · RS rating 72 · As of 2026-11-03
| Price | 2.61 USD |
|---|---|
| 1-day change | +1.9% |
| RS rating (overall / 1M / 3M / 12M) | 72 / 47 / 79 / 60 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 32 / 63 / 14 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -77.3% |
| Sales growth Q/Q | -48.9% |
| Distance from 52-week high | +17.1% |
| Market cap (USD) | $172.4M |